SCP
REGN icon

Sivia Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Sivia Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-498
Closed -$316K – 456
2025
Q1 		$316K Buy
498
+155
+45% +$107K 0.15% 146
2024
Q4 		$244K Buy
343
+66
+24% +$55.4K 0.12% 146
2024
Q3 		$291K Buy
277
+7
+3% +$7.79K 0.17% 122
2024
Q2 		$284K Sell
270
-1
-0.4% -$969 0.19% 123
2024
Q1 		$261K Hold
271
– – 0.18% 133
2023
Q4 		$238K Buy
+271
New +$223K 0.18% 136

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sivia Capital Partners's REGN Position: Q2 2025 in Review

Sivia Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 498 shares — an estimated $316K sold.

Sivia Capital Partners first reported a position in REGN in Q4 2023 and held it in 6 quarters. The position peaked at $316K in Q1 2025. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Sivia Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sivia Capital Partners sold 498 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $316K.
  • Sivia Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Sivia Capital Partners's Regeneron Pharmaceuticals position peaked at $316K in Q1 2025.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Sivia Capital Partners's 13F filing for Q2 2025, filed 9 Jul 2025.